Immunophenotype of normal and myelomatous plasma-cell subsets

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Robillard, Nelly ^a   Wuillème, Soraya ^a   Moreau, Philippe ^a   Béné, Marie C ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Bone marrow; Flow cytometry; Immunophenotype; Multiple myeloma; Plasma cells

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; IMMUNOGLOBULIN LIGHT CHAIN; STEM CELL FACTOR RECEPTOR; SYNDECAN 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL CLONE; CELL HETEROGENEITY; CELL SUSPENSION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL;

EID: 84897936528     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00137     Document Type: Article

References (25)

1. Tatsas AD, Jagasia MH, Chen H, McCurley TL. Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis? Am J Clin Pathol (2010) 134:139-44. doi: 10.1309/AJCP69TCAVDGSCWI
2. Guikema JE, Hovenga S, Vellenga E, Bos NA. Heterogeneity in the multiple myeloma tumor clone. Leuk Lymphoma (2004) 45:857-71. doi:10.1080/10428190310001593201
3. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica (2006) 91:1234-40.
4. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol (2010) 149:334-51. doi:10.1111/j.1365-2141.2010.08121.x
5. Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME, et al. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom (2010) 78:231-8. doi:10.1002/cyto.b.20517
6. Rawstron AC. Immunophenotyping of plasma cells. Curr Protoc Cytom (2006) 6:6.23. doi:10.1002/0471142956.cy0623s36
7. Robillard N, Béné MC, Moreau P, Wuillème S. A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J (2013) 3:e134. doi:10.1038/bcj.2013.33
8. Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom (2011) 80:318-23. doi:10.1002/cyto.b.20601
9. Medina F, Segundo C, Campos-Caro A, González-García I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood (2002) 99:2154-61. doi:10.1182/blood.V99.6.2154
10. Mateo G, Castellanos M, Rasillo A, Gutiérrez NC, Montalbán MA, Martín ML, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 11:3661-7. doi:10.1158/1078-0432.CCR-04-1489
11. Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2013) 27:473-81. doi:10.1038/leu.2012.226
12. Arnoulet C, Béné MC, Durrieu F, Feuillard J, Fossat C, Husson B, et al. Four-and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom (2010) 78:4-10. doi:10.1002/cyto.b.20484
13. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica (2004) 89:547-51.
14. Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, et al. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. J Clin Pathol (2012) 65:823-9. doi:10.1136/jclinpath-2012-200881
15. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 23:433-51. doi:10.1016/j.beha.2010.09.002
16. Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom (2010) 78:239-52. doi:10.1002/cyto.b.20512
17. Ocqueteau M, Orfao A, García-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol (1996) 95:489-93. doi:10.1111/j.1365-2141.1996.tb08993.x
18. Montero JC, López-Pérez R, San Miguel JF, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica (2008) 93:851-9. doi:10.3324/haematol.12171
19. Schmidt-Hieber M, Pérez-Andrés M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, Vidriales MB, et al. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica (2011) 96:328-32. doi:10.3324/haematol.2010.031872
20. Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 26:2737-44. doi:10.1200/JCO.2007.15.4120
21. Cannizzo E, Carulli G, Del Vecchio L, Ottaviano V, Bellio E, Zenari E, et al. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. Am J Clin Pathol (2012) 137:377-86. doi:10.1309/AJCP63TOCFNAMDMS
22. Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res (2008) 32:379-82. doi:10.1016/j.leukres.2007.07.016
23. Grigoriadis G, Gilbertson M, Came N, Westerman D, Fellepa F, Jene N, et al. Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature. Pathology (2012) 44:552-6. doi:10.1097/PAT.0b013e3283583f5d
24. Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, et al. Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 21:835-6.
25. Robillard N, Wuillème S, Lodé L, Magrangeas F, Minvielle S, Avet-Loiseau H. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia (2005) 19:2021-2. doi:10.1038/sj.leu.2403948